MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Minerva Neurosciences Inc

Uždarymo kaina

1.53 -8.93

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.48

Max

1.71

Pagrindiniai rodikliai

By Trading Economics

P/E

Sektoriaus vid.

8.167

63.778

Darbuotojai

8

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+194.12% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-04-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.9M

11M

Ankstesnė atidarymo kaina

10.46

Ankstesnė uždarymo kaina

1.53

Minerva Neurosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-04-01 23:46; UTC

Rinkos pokalbiai

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025-04-01 23:43; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

2025-04-01 23:11; UTC

Svarbiausios naujienos

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

2025-04-01 23:02; UTC

Rinkos pokalbiai

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

2025-04-01 22:31; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 22:26; UTC

Rinkos pokalbiai

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

2025-04-01 21:47; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 21:32; UTC

Svarbiausios naujienos

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

2025-04-01 21:06; UTC

Rinkos pokalbiai

Mexican Remittances See Slow Start to the Year -- Market Talk

2025-04-01 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-04-01 20:47; UTC

Svarbiausios naujienos

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

2025-04-01 20:47; UTC

Svarbiausios naujienos

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

2025-04-01 20:20; UTC

Svarbiausios naujienos

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

2025-04-01 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Fibrebond >ETN

2025-04-01 20:11; UTC

Rinkos pokalbiai

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

2025-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

2025-04-01 20:00; UTC

Svarbiausios naujienos

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

2025-04-01 19:46; UTC

Svarbiausios naujienos

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

2025-04-01 19:43; UTC

Rinkos pokalbiai

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

2025-04-01 19:17; UTC

Svarbiausios naujienos

Meta's Head of AI Research to Resign Amid Computing Push -- Update

2025-04-01 19:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Give Back Gains -- Market Talk

2025-04-01 19:03; UTC

Rinkos pokalbiai

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

2025-04-01 19:00; UTC

Rinkos pokalbiai

Gold Slips Ahead of Tariff Day -- Market Talk

2025-04-01 18:54; UTC

Rinkos pokalbiai

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Akcijų palyginimas

Kainos pokytis

Minerva Neurosciences Inc Prognozė

Kainos tikslas

By TipRanks

194.12% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  194.12%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Minerva Neurosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

0

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

$

Apie bendrovę Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.